ESC Heart & Stroke 2021

ESC Heart & Stroke 2021

6th April 2021

2-4th June 2021 | E-Conference

Who?

The International Conference of the ESC Council on Stroke is an educational conference for clinicians. It is designed not only for cardiologists, but also for neurologists, radiologists, vascular surgeons, neurosurgeons whose work has a component in “stroke”.

When?

2-4 June 2021 – Afternoon sessions

This format will allow the members to join the sessions that are professionally most relevant to their daily practice

What?

KOL‘s from a wide range of specialties will discuss multidisciplinary and focused aspects with emphasis on the latest developmentspractical experience sharing and guidelines illustration in the light of the latest research

 

Join this interactive conference and benefit of the opportunity to present your poster and share your work with large ESC family audience

BCS Emerging Leaders Programme

BCS Emerging Leaders Programme

26th March 2021

Call for Expressions of Interest – Nurses and Radiographers

Dear Colleagues

The BCS is seeking applications from nurses and radiographers who would be interested in being delegates on this highly prestigious course for EMERGING LEADERS. The objective is to provide training and support for experienced Cath Lab nurses and radiographers with the ambition to seek/apply for senior leadership roles.

I should point out that the opportunity is also open to physiologists, but the BCS is pursuing this via their own physiologists’ society route.

The following links provide the draft programme for this year’s event and an idea of the selection criteria and application.

This is an exciting opportunity for BCIS members.

Good luck!

Prof. Nick Curzen
President, British Cardiovascular Intervention Society

Valve for Life UK

Valve for Life UK

10th February 2021

Dear Colleagues,

Valve for Life is an EAPCI initiative to increase delivery of trans-catheter valve therapies in member countries with under-penetration of valve intervention. Following successful VfL initiatives in Poland, Portugal, and France, the United Kingdom was approved by EAPCI in 2020.

As part of the initiative the UK Valve for Life Group have launched a website (https://www.valveforlife.co.uk/) which we hope will serve as a valuable resource for both clinical teams involved in valve interventions and their patients. It houses patient information documents and videos, patient stories and decision aids, as well as up-to-date UK TAVI statistics, service specifications, the latest international guidelines, and key trial publications. Most of this material can be downloaded for your personal use. The website is currently focused on TAVI, but will in due course encompass other valve interventions.

Please visit the site, and publicise it to your patients and primary and secondary care colleagues.

If you have any suggestions, or information you feel should be included please contact any of the Valve for Life team (Dan Blackman (Chair), Noman Ali, Clare Appleby, Jonathan Byrne, Sam Dawkins, Phil MacCarthy, John Rawlins, Uday Trivedi). This can also be done via the website.

With best wishes,

Dan Blackman, (Chair, VfL) and Clare Appleby (Honorary Secretary, BCIS), on behalf of the Valve for Life Team.

The Future of TAVI in the UK

The Future of TAVI in the UK

18th September 2020

Aortic Stenosis is a ticking time bomb and many patients may die while waiting for AVR with 40% of patients on a waiting list requiring unplanned hospital admission in approximately a four-month period.

In the current context of the treatment for patients with aortic stenosis, Edwards Lifesciences would like to help contribute to the Heart Team Community by facilitating a webinar on future considerations for aortic stenosis patients for optimal treatment with minimal hospital footprint.

The Webinar will be entitled “The Future of TAVI in the UK” and will feature talks from Prof. Nick Curzen on the BCIS vision for the future and Dr Dan Blackman on the UK Valve For Life mission. The webinar will be chaired by Prof. Philip MacCarthy and live Q&A session panel discussion including Prof. Neil Ruparelia, Hammersmith Hospital, London, Mr Wil Woan, Heart Valve Voice as well as Prof. Nick Curzen and Dr Dan Blackman.

If you are interested in this event, please click the link below to find out more and register. 

The Management of Aortic Stenosis in Today’s Future: Watch Online

The Management of Aortic Stenosis in Today’s Future: Watch Online

27th May 2020

Now Available To Watch On-Demand

On Wednesday 20th May Edwards Lifesciences hosted a webinar titled: The Management of Aortic Stenosis in Today’s Future, aiming to address the current guidance, challenges and today’s future for TAVI when treating patients with Aortic Stenosis.

The webinar was presented by Prof. Simon Redwood (St Thomas‘s Hospital, London), Prof. Nick Curzen (BCIS President, Southampton General Hospital), Prof. Neil Ruparelia (Hammersmith Hospital, London), Prof. Rajesh Kharbanda (Oxford University Hospital), Dr. Sagar Doshi (Queen Elizabeth Hospital, Birmingham) and Dr. Iqbal Malik (Hammersmith Hospital, London).

Each presenter shared their throughs and experiences in a different area of aortic stenosis management:

  • Prof. Simon Redwood: Welcome and Introduction
  • Prof. Nick Curzen: Current Situation and Guidance
  • Prof. Neil Ruparelia: The Management Challenge of Aortic Stenosis in the COVID 19 Crisis
  • Dr. Sagar Doshi: Re-starting Elective TAVI – Risk Stratification
  • Prof. Rajesh Kharbanda: The Practicalities of Doing Even One TAVI in the COVID 19 Era
  • Panel discussion and Q&A

The webinar was recorded and is now available to watch on-demand via the link below. 

The Management of Aortic Stenosis in Today’s Future

The Management of Aortic Stenosis in Today’s Future

14th May 2020

In the current context of the treatment and referral for patients with aortic stenosis, Edwards Lifesciences would like to help contribute to the Heart Team Community by facilitating a webinar to address the current guidance, challenges and today’s future for TAVI when treating patients with Aortic Stenosis.

The Webinar will be entitled “The Management of Aortic Stenosis in Today’s Future” and will be co-presented by Prof. Nick Curzen (President of BCIS, Southampton General Hospital), Prof. Simon Redwood (St Thomas’s Hospital, London), Prof. Neil Ruparelia (Hammersmith Hospital), Prof. Rajesh Kharbanda (Oxford University Hospital), Dr Iqbal Malik (Hammersmith Hospital) and Dr Sagar Doshi (Queen Elizabeth Hospital, Birmingham).

The webinar will take place Wednesday 20 May 2020, 17:00-18:00 (UK).

Topics covered include:

  • Current AS treatment and guidance.
  • The management challenges of Aortic Stenosis patients in the COVID-19 crisis.
  • Re-starting elective TAVI and the risk stratification for patients.
  • The practicalities and logistics of performing TAVI in the COVID-19 era.

A significant part of the webinar agenda will be dedicated to a Q&A session and therefore, we would encourage you to submit any questions you may have in advance here. However, questions can be asked during the live event.

In case you cannot attend this webinar, recordings will be available after the event which can be shared with you.

We hope that this educational format will be of interest and value to you and we wish you good health and safety in this unprecedented time.

For more information on the event, click here

Public Health England (PHE) PPE Guidelines

Public Health England (PHE) PPE Guidelines

6th April 2020

Dear Colleagues,

Public Health England (PHE) have now produced updated guidance on recommended PPE, endorsed by the four Chief Medical Officers, which is attached. We would like to offer some guidance that interprets these principles in the context of cardiology-specific scenarios.

This guidance adopts an approach in which the PPE strategy is dependent upon both (a) the location in which patient contact occurs and (b) the likelihood that the contact will involve an aerosol generating procedure (AGP).

For cardiology, this applies to any procedure requiring or likely to require resuscitation for cardiac arrest involving CPR ± intubation and to transoesophageal echocardiography. These procedures require disposable gloves, fluid resistant gowns, a filtering face piece respirator and eye/face protection wherever they are performed (termed type 2 PPE). Other procedures require disposable gloves, plastic apron (when not scrubbed), fluid resistant surgical mask and eye protection (termed type 1 PPE).

Ward environments are covered within the PHE guidance.

For catheter lab procedures the PHE guidance can be applied to the individual case by the assessment of the senior clinician, together with senior cath lab staff, taking into account (a) the likelihood that the patient has the virus and (b) the chance the procedure will be AGP. Our recommendations for the catheter lab are:

For primary PCI and other situations where the patient is admitted directly to the lab or via a resuscitation area in a haemodynamically unstable state the default is that the first operator, assistant and others with direct patient contact (within 1 metre) should wear type 2 PPE.
Note 1. It may well be the case that in many catheter labs, every member of staff will be within 1 metre of the patient at some point during the case. Note 2. If some members of staff are not wearing type 2 PPE and there is a cardiac arrest, those staff should leave the lab immediately and only return if wearing full PPE.

For patients admitted to the lab already intubated or where there is felt to be a very high risk of arrest with prolonged resuscitation then all those within the lab to wear type 2 PPE.

For other situations the cath lab, when deemed low risk of AGP, can be regarded as an inpatient area or operating theatre with suspected or confirmed COVID cases and type 1 PPE is recommended for all those with direct patient contact (within 1 metre).

We recognise that there is a divergence of views within cardiology; we offer here a consensus to advise our members how they can approach PPE for the procedures they undertake and hope that this will provide some clarity.

Recommended PPE for healthcare workers by secondary care inpatient clinical setting, NHS and independent sector 

COVID-19 Safe ways of working: A visual guide to safe PPE 

Nick Curzen
President
British Cardiovascular Intervention Society

Simon Ray
President
British Cardiovascular Society

Alistair Slade
President Elect
BHRS

Important information from the Competitions and Markets Authority: Your requirements as ‘private’ consultants

Important information from the Competitions and Markets Authority: Your requirements as ‘private’ consultants

30th September 2019

As you know, consultants who offer private treatment services are under a legal obligation to be transparent about the typical fees they charge patients for private consultations and procedures.

The Private Healthcare Information Network (PHIN) has been set up as a one-stop shop for patients to find all the information they need when considering a private procedure, and as it grows it is important for consultants to have a presence there – so they can be found by new patients, as well as to fulfil their legal obligations.

PHIN has been mandated to collect performance and costs information and publish this information to better inform patients on their website, following an investigation by the Competition and Markets Authority (CMA) in 2014, which found a lack of transparency in the costs that patients can expect to pay when accessing private care. The lack of transparency is particularly felt by those who self-fund. This is the group that often has the least information about the cost of their procedure and are most vulnerable to unforeseen charges.

PHIN will also be publishing performance information on consultants, provided by the private and NHS hospitals at which they work. Consultants can review the information PHIN holds on them to check it for accuracy and completeness, to ensure that patients get reliable information on the consultants who treat them. To log onto the PHIN consultant portal please use this link: https://portal.phin.org.uk

These requirements are part of the Private Healthcare Market Investigation (Variation and Commencement) Order 2017.

PHIN has provided a range of support guides for consultants new to the process:

Guide to logging onto the PHIN Portal

https://portal.phin.org.uk/Lists/Resource/PHIN%20Portal%20Log%20in%20steps.pdf

Guide to submitting fees to PHIN

https://portal.phin.org.uk/Lists/Resource/PHIN%20Consultant%20fee%20submission.pdf

We encourage all consultants that see patients on a private basis to engage proactively with this process. This is not only a legal requirement, but is also important for providing patients with all the necessary information when considering their care. It’s also useful for you to have a presence on PHIN, so new prospective patients can find you.

If you have any questions please don’t hesitate to contact the PHIN team at consultants@phin.org.uk

Reopro / Abciximab national stocks running low

Reopro / Abciximab national stocks running low

9th October 2017

See document for full details

 

In summary

• There is a temporary interruption of supply for ReoPro® that is likely to result in shortages to patients for the time period between October 2017 and March 2018.

• We estimate that hospital pharmacies will be out of stock by October 2017 or earlier.

• Please consider alternative medications such as other glycoprotein IIb/IIIa antagonists or Bivalirudin instead of ReoPro.